Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists - Wikidata - wikimedia - TriplyDB

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

http://www.wikidata.org/entity/Q27661999

about

Adhesive Pili in UTI Pathogenesis and Drug Development Adhesins Involved in Attachment to Abiotic Surfaces by Gram-Negative Bacteria Catch-bond mechanism of the bacterial adhesin FimH.Solution NMR structure of BT_0084, a conjugative transposon lipoprotein from Bacteroides thetaiotamicron Validation of Reactivity Descriptors to Assess the Aromatic Stacking within the Tyrosine Gate of FimH The tyrosine gate of the bacterial lectin FimH: a conformational analysis by NMR spectroscopy and X-ray crystallography The Antiadhesive Strategy in Crohn's Disease: Orally Active Mannosides to Decolonize Pathogenic Escherichia coli from the Gut Nitazoxanide Inhibits Pilus Biogenesis by Interfering with Folding of the Usher Protein in the Outer Membrane Structures of C-mannosylated anti-adhesives bound to the type 1 fimbrial FimH adhesin Mutation of Tyr137 of the universal Escherichia coli fimbrial adhesin FimH relaxes the tyrosine gate prior to mannose binding.Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay.Cystitis: from urothelial cell biology to clinical applications.A molecular-modeling toolbox aimed at bridging the gap between medicinal chemistry and computational sciences.Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection.Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection.Surfaces Presenting α-Phenyl Mannoside Derivatives Enable Formation of Stable, High Coverage, Non-pathogenic Escherichia coli Biofilms against Pathogen Colonization Fluorescence polarization assays in small molecule screening.Lead optimization studies on FimH antagonists: discovery of potent and orally bioavailable ortho-substituted biphenyl mannosides Designed ankyrin repeat proteins as scaffolds for multivalent recognition Combinatorial small-molecule therapy prevents uropathogenic Escherichia coli catheter-associated urinary tract infections in mice.Structure, Function, and Assembly of Adhesive Organelles by Uropathogenic Bacteria Antivirulence Isoquinolone Mannosides: Optimization of the Biaryl Aglycone for FimH Lectin Binding Affinity and Efficacy in the Treatment of Chronic UTI.Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection.Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era.Drug and Vaccine Development for the Treatment and Prevention of Urinary Tract Infections.Treatment and prevention of urinary tract infection with orally active FimH inhibitors.Targeting the bacteria-host interface: strategies in anti-adhesion therapy.Urinary tract infections: current and emerging management strategies.A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131.Profile of Scott J. Hultgren.From physiology to pharmacy: developments in the pathogenesis and treatment of recurrent urinary tract infections Anti-adhesion methods as novel therapeutics for bacterial infections.Bacterial surface appendages as targets for novel antibacterial therapeutics.Chondroitin Sulfate Tetrasaccharides: Synthesis, Three-Dimensional Structure and Interaction with Midkine.Urinary tract infection of mice to model human disease: Practicalities, implications and limitations.The unexplored relationship between urinary tract infections and the autonomic nervous system.Mannose-derived FimH antagonists: a promising anti-virulence therapeutic strategy for urinary tract infections and Crohn's disease.Target-directed Dynamic Combinatorial Chemistry: A Study on Potentials and Pitfalls as Exemplified on a Bacterial Target.Escherichia coli biofilm: development and therapeutic strategies.Anti-virulence Strategies to Target Bacterial Infections.

P2860

Q26752944-F1534375-65D4-4E7B-B67F-EEBAC6419582 Q26782609-B17191A8-872E-4B2B-BA8D-55234CA02A34 Q27331629-469A7217-4EB3-4089-97B5-8ADC2BD3F12E Q27675795-1D8C36A7-C758-4D90-BC0D-C64A335C26E5 Q27684171-D3F8CDB1-08E2-4013-B4D4-20F78A9D5610 Q27700666-8BC929AF-B4A8-455C-B74D-6F06A9C49561 Q27704226-835EDDA8-B9BF-433B-AD97-312F7109FBD1 Q30277655-F2E2AAF5-B078-4BF5-9EBA-3ECB58F2E7FD Q30387877-2FCD70BB-A02E-4662-8172-E350DB66DBBD Q30399333-3F55EC9D-863E-42F7-8A1D-EC0758F832AF Q30574395-DBE8AB0A-1C69-481A-AEBD-B4E913EF5948 Q33616113-485E25D0-B292-45BA-BA93-0CC7EB1E4E86 Q34560190-5959928E-34D6-4F50-BB24-6160D8694BDB Q34876396-B01AB569-77D5-482A-AA0D-1BCB1DC45EAB Q35273075-3FCDB471-CE1F-4D32-8FFB-B6211B51FDB2 Q35646966-D9B24EA6-2C02-4CA8-A6BF-75D4F53E764C Q35750597-2656CE5A-0146-4BD1-AE8F-1A73D817CEAB Q36032748-184E03BD-83ED-4189-A9F4-645655E71F82 Q36099748-C601258D-94B9-4ED3-B13C-91F807123D66 Q36172411-F3A069ED-6EE2-4A24-9245-0590262C4404 Q36263415-1D047C48-D372-4940-8D46-C779F7B487A6 Q36760050-4528DE58-13C4-4246-96CD-A71A1B425750 Q36910650-61B79D49-C39E-46DA-9AC8-7BE30692B14B Q36933039-4B4BDD92-DD63-4486-BEA1-676A9BFD2227 Q36951570-35DBA607-FC56-47C8-A5B6-BFD9436AAE5E Q36961034-FC7D3E61-5D91-4117-94F1-A3686E93E7FC Q37009022-4126CC0F-1584-48DE-886F-F473105F9FED Q37084979-72630CB2-91CA-4BDF-9821-B4ECA485481A Q37109522-B8B11EBD-E5D6-4F76-AC65-964D64B6CC33 Q37203955-2FD6847E-AF32-4F12-8EC5-3DEC487025CC Q37230837-D303CBFC-2E95-48B4-87C0-84270806151D Q38068610-1427BE88-2195-4CD8-87A7-E050F5568421 Q38243219-32B9AF54-AD9F-486E-B9C7-E2D68BF59C06 Q38294264-CEE03FFF-C84E-42FF-A3E9-B38D8F6FFFE9 Q38501348-F425DBCA-727E-4368-8AC8-2D285D398363 Q38537188-1B2AFF63-DAE2-4A73-8931-F269D6A0D51E Q38664310-29B96F52-7DF5-4B35-B425-CFB6939D67EB Q38706795-FE7B3397-081A-48BE-9DCB-2E46DAC4271E Q38711844-C5964A93-F3E2-40C6-9FE8-DA5868494C66 Q38760476-CC0124A8-670D-4EAB-8B9E-D6CFEFEF23DA

P2860

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

http://www.wikidata.org/entity/Q27661999

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@ast

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@en

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@nl

type

label

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@ast

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@en

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@nl

prefLabel

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@ast

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@en

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@nl

P1433

Q27661999-D9943813-0CFC-400C-80AD-60B36E1D216C

P1476

Q27661999-F3CD46C3-F089-4E7F-9C89-2958461D0F85

P2093

Q27661999-88779C9C-23DE-4D1F-BC92-227DDE4CB7EA

Q27661999-A125200E-006E-4843-A592-F86E9DDEC8D2

Q27661999-ADDF21AF-888F-49B5-9C80-9A391E92DE8B

Q27661999-B1D11F4D-6590-49EC-995C-68E411A8C60B

Q27661999-B6D40B37-36CE-4A06-B62F-F6FA5476BADB

Q27661999-BF28912E-2E15-4F82-B237-4A1445E70C84

Q27661999-CC043AD4-A448-4EB6-89BA-9C2EA246E43E

Q27661999-D5C5D7B1-2E58-44A8-8811-6D38FAB4BCC9

Q27661999-D6A161A8-5BB1-4D29-A761-C638D72E3A79

P2860

Q27661999-0995856A-8A96-4D30-AB10-13763F52811F

Q27661999-1649A291-F1C6-4C88-B0CE-0AF2FE0D2376

Q27661999-17DA7DA1-CE44-4BA7-AAF9-B7AC2E477192

Q27661999-186B2C30-0912-4E25-82A6-0A7EC42921CC

Q27661999-18BF5C52-3CD8-4531-96B8-789605FE494B

Q27661999-19577C8D-B0AE-496A-B008-25EBEFF0F831

Q27661999-19DEE109-56F9-4A34-8309-D75FA9AA154A

Q27661999-1E050B58-00FB-4C17-B314-D739CF1A3E7C

Q27661999-2459DBDC-6C54-47EF-BD40-983C029B13B8

Q27661999-2A29DED9-BF26-4072-9D1D-50266CF1CADD

P304

Q27661999-F813A9AD-6A7B-4604-A6C9-597A49E6FC05

P31

Q27661999-31E44ECA-D58E-4AA8-91EE-F7168A2F6CF6

P356

Q27661999-6EE306D6-7CBC-4D57-9389-A2B6F1C8135E

P407

Q27661999-1F5D9A45-5137-4A99-AD1E-83476FA1EC6D

P433

Q27661999-9ED7CD22-46BF-4C41-BAC3-49F53D120070

P478

Q27661999-EE345EE5-D9F1-45B8-A206-984172A27E38

P50

Q27661999-2A2D89AF-5C2B-43DD-8F7D-E203F5F288A6

Q27661999-AF0F044F-CB7A-4EE0-900B-D7A454BD7C7B

P577

Q27661999-322ED84B-3B86-4057-8760-68A2BC715D08

P5875

Q27661999-F59E64FC-150B-4F25-BE6C-6131DB4EB271

P698

Q27661999-C90A2AAE-9123-4B12-8089-DD6AFF7CFE79

P921

Q27661999-5B3031E6-3D68-43A9-8B31-6926BDC10C3F

Q27661999-F1F8C80B-3453-420B-AE14-3978D0464997

P932

Q27661999-4CC777FA-9149-40F4-B4B0-F131368023EC

P356

P1433

Journal of Medicinal Chemistry

P1476

Structure-Based Drug Design and Optimization of Mannoside Bacterial FimH Antagonists

@en

P2093

Bradley Ford

http://www.w3.org/2001/XMLSchema#string

Corinne K Cusumano

http://www.w3.org/2001/XMLSchema#string

Doug Hobbs

http://www.w3.org/2001/XMLSchema#string

James W Janetka

http://www.w3.org/2001/XMLSchema#string

Jerome S Pinkner

http://www.w3.org/2001/XMLSchema#string

Robert Obermann

http://www.w3.org/2001/XMLSchema#string

Scott A Wildman

http://www.w3.org/2001/XMLSchema#string

William Nolan

http://www.w3.org/2001/XMLSchema#string

Zhenfu Han

http://www.w3.org/2001/XMLSchema#string

P2860

Electrostatics of nanosystems: application to microtubules and the ribosome

Aromatic alpha-glycosides of mannose are powerful inhibitors of the adherence of type 1 fimbriated Escherichia coli to yeast and intestinal epithelial cells

Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex

Filamentation by Escherichia coli subverts innate defenses during urinary tract infection

Structural basis of tropism of Escherichia coli to the bladder during urinary tract infection

Phasercrystallographic software

Refinement of macromolecular structures by the maximum-likelihood method

Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination

electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation

Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis.

P304

4779-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/JM100438S

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

Tom Ellenberger

Scott J. Hultgren

P577

2010-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44634769

http://www.w3.org/2001/XMLSchema#string

P698

20507142

http://www.w3.org/2001/XMLSchema#string

P921

Methyl alpha-D-mannoside

P932

2894565

http://www.w3.org/2001/XMLSchema#string